Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxneuvance in HIV-Infected Adults (PNEU-WAY)
NCT03480802Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 5
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jul 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03480802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480802.